Adjuvant immunotherapy improves disease-free survival in residual esophageal squamous cell carcinoma
Across 2,090 patients with residual esophageal squamous cell carcinoma, adjuvant immunotherapy was associated with improved disease-free survival, while overall survival benefit remained uncertain.